期刊文献+

The surgical prognosis of pIIIA/N2 non-small-cell lung cancers

pIIIA/N2期非小细胞肺癌患者外科治疗的预后分析(英文)
在线阅读 下载PDF
导出
摘要 Objective: The aim of the study was to identify prognostic factors in non-small-cell lung cancer (NSCLC) with N2 nodal involvement.Methods: A retrospective analysis of disease free survival and 5-year survival for NSCLC patients who underwent primary surgical resection without neoadjuvant chemotherapy were performed.Between January 1998 and May 2004,133 patients were enrolled.Several factors such as age,sex,skip metastasis,number of N2 lymph node stations,type of resection,histology,adjuvant therapy etc.,were recorded and analyzed.SPSS 16.0 software was used.Results: Overall 5-year survival for 133 patients was 32.33%,5-year survival for single N2 station and multiple N2 stations sub-groups were 39.62% and 27.50% respectively,and 5-year survival for cN0–1 and cN2 sub-groups were 37.78% and 20.93% respectively.COX regression analysis revealed that number of N2 station (P = 0.013,OR: 0.490,95% CI: 0.427–0.781) and cN status (P = 0.009,OR: 0.607,95% CI: 0.372–0.992) were two favorable prognostic factors of survival.Conclusion: Number of N2 station and cN status were two favorable prognostic factors of survival.In restrict enrolled circumstances,after combined therapy made up of surgery and postoperative adjuvant therapy have been performed,satisfied survival could be achieved.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2011年第1期9-14,共6页 中德临床肿瘤学杂志(英文版)
关键词 non-small-cell lung cancer (NSCLC) N2 metastasis PROGNOSIS 非小细胞肺癌 手术切除 预后 辅助治疗 存活率 SPSS 回归分析 手术治疗
  • 相关文献

参考文献20

  • 1National Cancer Institute. Surveillance, epidemiology and end results (SEER) data. http://seer.cancer.gov/. Accessed Jun 5, 2008.
  • 2van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst, 2007, 99: 442-450.
  • 3Detterbeck F. What to do with "Surprise" N27: intraoperative management of patients with non-small cell lung cancer. J Thorac Oncol, 2008, 3: 289-302.
  • 4NCCN clinical practice guidelines in oncology, www.nccn.org. Nonsmall cell lung cancer. V2. 2009.
  • 5Mountain CF. Revisions in the international system for staging lung cancer. Chest, 1997, 111: 1710-1717.
  • 6Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of non- small cell lung cancer - stage IliA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007, 132: 2435-2655.
  • 7Friedel G, Steger V, Kyriss T, et al. Prognosis in N2 NSCLC. Lung cancer, 2004, 45 Suppl 2: S45-53.
  • 8Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol, 2000, 18: 2981-2989.
  • 9Cerfolio R J, Bryant AS, Eloubeidi MA. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non- small cell lung cancer who are clinically N2 negative: a prospective study. Chest, 2006, 130: 1791-1795.
  • 10Meyers BE Haddad F, Siegel BA, et al. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. J Thorac Cardiovasc Surg, 2006, 131:822-829.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部